Center for Disease Analysis Foundation
CAMEO INITIATIVE AGREEMENT

This CAMEO Initiative Agreement ("**Agreement**") is entered into as of XXXXXXX (the "**Effective Date**"), by and between Center for Disease Analysis Foundation, Inc., a Colorado corporation with business offices at 1120 W South Boulder Rd, Suite 102, Lafayette, Colorado 80026 ("**CDAF**"), and NAME, a COUNTRY nonprofit corporation located at ADDRESS ("**Recipient"**). CDAF and Recipient are hereafter collectively referred to as "**Parties**" and each may individually be referred to as a "**Party**."

BACKGROUND

The mission of the CAMEO Initiative (the "**Program**") is to support initiatives that empower patients, foster education, and drive meaningful change through advocacy-led programs. This project is being made possible through an award by Gilead Sciences, Inc.

Recipient has submitted a proposal for the Program pursuant to the submission requirements of the Program, and CDAF wishes to provide financial support by way of an Award (as defined below) to Recipient with respect to Recipient's (as defined below) capacity to achieve the Program Goals.

In consideration of the mutual covenants, promises, agreements, representations, and warranties contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby certify, promise, and agree as follows:

1. Definitions. For purposes of this Agreement, the following words and phrases shall have the following meanings:

"**Award**" has the meaning set forth in Section 3(a) of this Agreement.

"**Recipient**" means the organization receiving an Award directly from CDAF, and with the responsibility of implementing the Program in accordance with Program Goals, the Proposal and Proposal Budget.

"**Recipient Lead**" means NAME OF PRIMARY INVESTIGATOR/S, the primary contact at the Lead Organization and author of the Proposal.

"**Other Affiliations**" means the Recipient Lead's other academic, advisory or business affiliations including, without limitation, consultant positions, scientific advisory appointments, directorships, academic positions, and employment.

"**Program Goals**" means the Program details set forth in the document titled *CAMEO Request for Proposals* document attached hereto as Exhibit A.

"**Proposal**" means the written description set forth in the Recipient's Application/Proposal Details in Exhibit B, which is attached hereto and incorporated herein by reference.

"**Proposal Budget**" means the budget for the Proposal set forth in the Budget Details in Exhibit C, which is attached hereto and incorporated herein by reference.

"**Proposal Timing**" means the timing for the Proposal set forth in the Budget Details in Exhibit D, which is attached hereto and incorporated herein by reference.

2. Proposal Implementation. Recipient will implement the activities set forth in the Proposal, as outlined in Exhibits B, C, and D. Any material change in the Proposal may be made solely by an amendment to this Agreement.

3. Award; Exclusive Use of Award.

(a) CDAF will provide Recipient up to XYZ dollars (**$XYZ.00)** for the Proposal (the "**Award**"), pursuant to the Proposal Budget in Exhibit C. The Award will be disbursed according to the milestone payments shown below. Recipient shall send an electronic invoice to CDAF to the individuals indicated on the invoice template which will be provided.

(b) CDAF will pay the invoice within 30 days.

Milestone payments

Milestone	**Payment**
1.	
2.	
3.	
4.	
5.	
6.	
7.	
8.	

(c) Recipient shall use the Award solely for the purpose of performance of the Proposal, under the direction of the Recipient Lead, and in accordance with the Proposal Budget, as outlined in Exhibit C. Recipient will not use the Award for its institutional indirect costs (with the exception of what is permissible under the approved Proposal Budget), overhead or general expenses. In the event that Recipient does not expend the total Award, Recipient will, unless otherwise agreed to by CDAF in its sole discretion, return such funds to CDAF within sixty (60) days of expiration or termination of this Agreement, or as requested by CDAF.

(d) Recipient understands and agrees that if the scope of the project outlined in the Recipient's Application/Proposal Details in Exhibit B is reduced by more than 10% the Award set forth in Section 3(a) of this Agreement, will be prorated to reflect the reduction unless otherwise agreed to by CDAF in its sole discretion.

(e) Recipient understands and agrees that Award funds should be used in accordance with Exhibits A and D and may not be transmitted to, or used to pay for or offset the cost of, the following:

(i) Medications, or purchasing of medications.

(ii) Direct medical expenses, including labs.

(iii) Existing deficits.

(iv) Basic biomedical research, clinical research, or clinical trials.

(v) Projects that include the purchase, utilization, prescribing, formulary position, pricing, reimbursement, referral, recommendation, or payment for pharmaceutical products.

(vi) Events or programs that have already occurred.

(vii) Individuals with prescribing authority or physician group practices.

(viii) Government lobbying activities.

(f) CDAF is not responsible for:

(i) expenditures which exceed the total amount of the Award,

(ii) expenditures made before the starting date of the Performance Period,

(iii) obligations incurred after the Performance Period has ended,

(iv) Proposal Budget modifications without prior CDAF approval, or

(v) any expenditures not in the approved Proposal Budget.

(g) Recipient has the right during the Term to receive grants and funds from others for any purpose. By doing so, Recipient does not violate any of the terms or conditions of this Agreement. However, if Recipient receives "duplicative funding" for the Proposal, Recipient will return such funds to CDAF within sixty (60) days from the date of notice provided by a

third party that Recipient will receive "duplicative funding". For the purposes of this Agreement, "duplicative funding" means any financial support, including in-kind, for essentially equivalent work proposed in the Proposal before or during the Term of this Agreement. Nothing in this Agreement entitles Recipient to additional awards, grants, financial support or payments of any kind from CDAF.

(h) Recipient understands and agrees that CDAF may be required to post or report to government entities all fees and expenses paid to Recipient under this Agreement in accordance with all applicable laws, including Section 6002 of the Patient Protection and Affordable Care Act. Recipient further agrees to provide, at CDAF's reasonable request, any information necessary for CDAF to make a required posting or reporting.

(i) Recipient understands and agrees that CDAF may disclose the provision of the Award, and that the disclosure may include the following information: the names of Recipient and Recipient Lead, a brief description of the proposal activity and/or the amount of the Award.

4. Representations and Certification.

(a) **By CDAF**. CDAF represents, certifies, and covenants to Recipient that:

(i) the Proposal is solely controlled by the Recipient. Neither CDAF nor its affiliates (including without limitation, any employee, agent, director, officer, shareholder, or contractor) will exert any influence or control over Recipient or the Proposal. Neither CDAF nor its affiliates (including without limitation, any employee, agent, director, officer, shareholder, or contractor) will exert any influence or control over how Recipient conducts the Program, provided that Recipient conducts the Program in accordance with the Proposal and this Agreement; and

(ii) the Award is not provided, directly or indirectly, as an inducement or reward for the prescription, recommendation, purchase, supply, sale, administration, formulary placement, or use of any Gilead's products or to promote Gilead' products. Further, the parties acknowledge and agree that Recipient is not required to purchase, order, or recommend to any DBU individuals any products manufactured or available through Gilead Sciences.

(b) **By Recipient**. Recipient represents, certifies to CDAF that:

(i) its performance will comply with all applicable laws, rules, regulations and guidelines including, without limitation, compliance with Regulatory Authorities;

(ii) it will comply with the terms and conditions of this Agreement and with the conditions set forth in Exhibit A;

(iii) All applications and associated activities must not make any mention to specific medicines, treatments or medical devices.

(iv) it will not discriminate on the basis of race, color, gender, religion, disability, sexual orientation, or gender identity or expression;

(v) it will, in writing, promptly notify CDAF if Recipient Lead discontinues the Proposal or leaves the Recipient;

(vi) Recipient and any of its personnel performing the Proposal (including, without limitation, Recipient Lead) shall: (i) not knowingly use in any capacity, in connection with the performance of its obligations under this Agreement any individual or entity who or that has been debarred or suspended under 21 U.S.C. §335(a) or (b), or any foreign equivalent thereof, or who is the subject of a conviction described in such section or any foreign equivalent thereof; and (ii) inform CDAF in writing immediately upon becoming aware if it or any individual or entity who or that is performing activities hereunder on its behalf is debarred, suspended or is the subject of a conviction described in 21 U.S.C. §335(a) or (b), or any foreign equivalent thereof, or if any action, suit, claim, investigation, or legal or administrative proceeding is pending or, to its knowledge, is threatened, relating to such debarment or conviction;

(vii) neither Recipient, nor any of its affiliates, nor any of their respective directors, officers, employees and agents (including, without limitation, Recipient Lead) (collectively, "**Recipient Representatives**") has taken any action, directly or indirectly, that would result in a violation of the Foreign Corrupt Practices Act of 1977, as amended (such act, including the rules and regulations thereunder, the "**FCPA**"), the Convention on Combating Bribery of Foreign Public Officials in International Business Transactions adopted by the Negotiating Conference of the Organization for Economic Co-operation and Development on 21 November 1997 (such convention, including the rules and regulations thereunder, the "**OECD Convention**"), the U.K. Bribery Act 2010 ("**Bribery Act**"), or any other applicable anti-bribery or anti-corruption laws, rules or regulations (collectively with the FCPA, the OECD Convention and the Bribery Act, the "**Anti-Corruption Laws**"). Recipient represents and certifies that it and Recipient's Representatives will not undertake any actions that may violate the Anti-Corruption Laws, including directly or indirectly offering, paying, promising to pay, or authorizing the giving of money or anything of value to any third party, including any government official or employee of any government department, agency or instrumentality thereof (including, but not limited to, any health or medical institutions which are owned or controlled by the government), for the purpose of inducing such third party to use his or her influence or position to assist in obtaining or retaining business for, directing business to, or securing an improper advantage for Recipient or CDAF. Recipient has and will continue to have necessary procedures in place to prevent bribery and corrupt conduct by Recipient and Recipient Representatives. Recipient also agrees that CDAF shall have the right, from time to time, upon written notice to Recipient,

to conduct an investigation and audit of Recipient's policies, books, records and accounts to verify compliance with the provisions of this Agreement. Recipient agrees to cooperate fully with such investigation, the method of which shall be at the sole discretion of CDAF. Without limiting any other remedies at law or at equity, CDAF may, at CDAF's sole discretion, terminate this Agreement for any violation of the Anti-Corruption Laws, in accordance with CDAF's contractual rights;

(viii) it has obtained any necessary approvals, including those of Other Affiliations of Recipient Lead, to enter into this Agreement and accept the Award hereunder; and

(ix) it has not entered into, and during the Term of this Agreement will not enter into, any agreement with or obligation to a third party that is inconsistent or conflicting with its obligations under this Agreement.

5. No Implied Rights in Intellectual Property. Except as expressly set forth in this Agreement, nothing in this Agreement grants either Party any rights or a license to any patent, patent application, copyright, trademark, know-how (whether patentable or unpatentable) or other intellectual property rights to the other Party.

6. Publications. Any information contained in publications, studies or presentation of research funded by the Award shall be made available to the public following such reasonable requirements or procedures as CDAF and Recipient may agree to from time to time. CDAF shall have a non-exclusive, irrevocable right to use, reproduce and distribute any publications, studies or data produced in the course of the Proposal for research and education purposes only. Recipient and Recipient Lead agree that any and all publications or public announcements by Recipient arising out of the Proposal/Program shall carry the following acknowledgment: "Supported by funding from Center for Disease Analysis Foundation, Inc. Center for Disease Analysis Foundation, Inc. has had no input into the development or content of these materials."

7. Reports and Meetings.

(a) Quarterly, Recipient is required to participate in a 30-minute progress report via a web-conference.

(b) Quarterly, Recipient is also required to participate in web-conference meeting with all other Recipients to share and compare best practices.

(c) Upon the completion of the Recipient Program, a final report on activities, developments and accomplishments must be submitted to CDAF no later than ninety (90) days following the end of the final Performance Period. The final report should be in narrative form, a maximum of five single-spaced pages long, and sufficiently comprehensive to describe work completed during the funding period and indicate the significance of the activities, developments and accomplishments.

(d) Recipient is required to submit reports of expenditures ("**ROE**s") detailing how the funding was spent. Recipient is responsible for the use of Award funds to support the activities and goals described in the Proposal and Proposal Budget and needs to maintain records and supporting documentation consistent with accounting practices generally accepted in the United States of America (GAAP). If requested by CDAF, these records must be made available, at reasonable times, for inspection by CDAF staff or its representatives.

(e) When Recipient Program extends over multiple years, Recipient is required to provide an interim ROE by December 31st of each calendar year detailing how the funding was spent, and the remaining funds (one page maximum).

(f) The timely submission of Reports by the deadlines specified in these Reporting Requirements is a mandatory condition of the Award from CDAF. Failure to comply with the Reporting Requirements can result in the suspension of a scheduled payment following the missed deadline and, when justified, in the termination or eventual rescission of the Award in accordance with the following procedures.

(g) In the event of a missed deadline for any interim progress report, CDAF will send Recipient written notification of the missed deadline and payment suspension and a revised submission deadline, which provides a last chance for Recipient to file the mandated Report(s). Recipient shall then be allowed thirty (30) days from the revised deadline in which to submit the mandated interim progress report(s). If such interim progress reports are not submitted to CDAF within the 30-day period following a revised submission deadline, Recipient will be considered in violation of the terms and conditions of the Agreement, and CDAF will terminate the Agreement and Award effective the date of the deadline. In addition, all remaining funds previously made on the Award under the Agreement must be returned to CDAF.

(h) Please be aware that once an Award has been rescinded, the submission of Reports will not reinstate the Award or final payment. However, submission of an approved final progress report will (1) remove the "no progress" disclaimer, (2) allow Recipient to retain all Award funds issued to date, and (3) release any pending legal action directly related to the repayment of funds provided under an Award that was rescinded for failure to provide the final progress report and ROE.

8. To the extent permitted by applicable law, Recipient shall indemnify and hold harmless CDAF and its directors, officers, employees, contractors or agents from any and all claims, losses, liabilities, damages, expenses and costs (including attorneys' fees and court costs) that are caused, directly or indirectly, due to the negligent acts or omissions by Recipient or its personnel in performance of the Proposal or breach of this Agreement (collectively, "**Claims**"), except to the extent any such Claim results from the gross negligence or willful misconduct of CDAF and its directors, officers, employees, contractors or agents.

9. Privacy Consent. The Parties shall comply with all Applicable Laws protecting the fundamental rights and freedoms of persons and Study Subject and, in particular, the right to privacy, with regard to the

processing of personal data including but not limited to as provided by the Health Insurance Portability and Accountability Act of 1996 ("HIPAA") and the General Data Protection Regulation 2016/679 ("GDPR") to the extent such regulation apply to the conduct of the Study ("Data Protection Laws").

Project: Recipient will not provide any personal DBU individual data to CDAF as part of its reporting including any personal data with such detail that may be used to identify any DBU individual. Non-personal data will be aggregated and analyzed by CDAF. Only results of aggregated data will be reported by CDAF.

Proposal, Budget & Reports: By including details on Recipient's Proposal, Proposal Budget and/or Report(s), Recipient and Recipient Lead each hereby consents to the processing of any personal information it has included in the Proposal, Proposal Budget and/or Report(s), and it confirms, to the best of its knowledge and belief, that it has the relevant rights and/or permissions to provide such personal information to CDAF. CDAF shall process such personal information for the purpose of conducting due diligence checks. Recipient also consents to being contacted by CDAF for the purposes of reviewing the Proposal, Proposal Budget and/or Report(s) and informing Recipient of the outcome of these due diligence checks.

Third Parties: Personal information provided by Recipient may be transferred to other third parties, such as the authorized consultants of CDAF, service providers of CDAF (or other carefully selected third-party organizations authorized by CDAF, together, referred to as "Third Parties") exclusively for the purpose of carrying out due diligence checks. CDAF will require these Third Parties to whom it discloses information Recipient and Recipient Lead have provided to protect such personal information using substantially similar standards to those required by CDAF, including an obligation on those Third Parties to use appropriate technical, administrative and physical safeguards to protect personal information the Recipient has provided from loss, misuse or alteration. CDAF also requires that such Third Parties do not use personal information the Recipient has provided for any purpose that is not specifically authorized by CDAF.

10. Term of Agreement and Termination.

(a) **Term of Agreement**. The term of this Agreement will begin on the Effective Date and will end upon fulfillment of all Reporting Requirements and completion of all payment obligations under this Agreement (the "**Term**"), unless terminated earlier in accordance with this Section.

(b) **Termination by Either Party.** Either Party may terminate this Agreement upon thirty (30) days written notice to the other Party for any reason.

(c) **Termination of Agreement for Specific Causes.** This Agreement may be terminated prior to expiration of the Term by:

(i) either Party, effective upon thirty (30) days written notice to the other Party, if the other Party commits a material breach of any of the terms of this Agreement and such

breach remains uncured for thirty (30) days after written notice of such breach has been furnished to the other Party;

(ii) CDAF, effective immediately upon written notice to Recipient, if Recipient loses its status as a not-for-profit organization; or

(iii) CDAF, effective immediately upon written notice to Recipient, in the event Recipient or Recipient Lead notifies CDAF that Recipient or Recipient Lead is unable or desires not to conduct the Proposal agreed to between the Parties herein, or Recipient Lead leaves the Recipient.

(d) **Effect of Termination.** Upon the expiration or termination of this Agreement for any reason, the rights and obligations that by their very nature should survive termination including, but not limited to, Sections 1, 3(b), 3(d), 3(e), 4(b)(iii), (vi)-(vii), 5, 6, 8, 9, 10(d) 11 and 12. In the case of any termination, Recipient will be required to return to CDAF any portion of the Award provided, but not yet expended, prior to the date of termination and any remaining Award funds will be canceled.

11. Relationship of the Parties. Recipient shall at no time hold itself out as an agent, partner, subsidiary or affiliate of CDAF for any purpose and shall have no authority to act on behalf of or bind CDAF to any obligation. Recipient's relationship with CDAF will be that of an independent contractor, and nothing in this Agreement shall be construed to create a partnership, joint venture, or employer-employee relationship. If Recipient is otherwise affiliated with a healthcare, academic or government (federal, state, or local government) institution or agency, Recipient represents that in entering this Agreement and performing the Proposal that Recipient (i) is complying with the applicable policies and procedures, if any, of the respective government agency or institution, (ii) has obtained any necessary approvals from the respective government agency or institution and (iii) may accept the Award from CDAF without creating a conflict of interest with Recipient's duties and/or obligations.

12. General.

(a) **Governing Law.** To the extent permitted by Recipient's state laws, this agreement is governed by the laws of the State of Colorado.

(b) **Notices.** Any notice or other communication required to be given or made under this Agreement shall be in writing and shall be given to the other Party as noted below. No communication or notice shall be effective if the Party to receive such communication or notice has notified the sender of a change in and provided a replacement address or principal contact person in accordance with the foregoing procedures for sending notices, unless such communication or notice is sent to the replacement address or principal contact person in accordance with the foregoing procedures.

Notices and communications shall be considered given or made where sent by hand or courier, upon receipt unless delivery is refused in which case on the date of refusal; or where sent by U.S. Mail, first class postage pre-paid, on the third working day following the date of posting; upon the receipt thereof to:

CDAF:
Center for Disease Analysis Foundation, Inc.
1120 W South Boulder Rd, Suite 102
Lafayette, Colorado 80026
Attn: Sarah Stone

RECIPIENT:
Name
Address
Attn:

(c) **Severability.** If any provision of this Agreement is held invalid, all other provisions of this Agreement shall remain in effect; provided, however, that the invalid provision may be modified by the Parties, an arbitrator or a court of law, as needed to make such provision valid.

(d) **Assignment.** Neither this Agreement nor any Award funds made available by CDAF hereunder shall be assigned by Recipient without the prior written consent of CDAF. Any purported assignment or delegation by Recipient of this Agreement in whole or in part without the prior written consent of CDAF shall be void.

(e) **Entire Agreement; No Waiver.** This Agreement and any exhibits constitute the entire agreement between the Parties concerning the subject matter hereof, superseding all prior and contemporaneous negotiations and discussions. No waiver, amendment or modification of any provision of this Agreement shall be effective unless in writing and signed by both Parties. Failure of either Party to enforce a right under this Agreement shall not act as a waiver of that right or the ability to later assert that right relative to the particular situation involved or to terminate this Agreement as a result of any subsequent default or breach.

(f) **Party that Drafted Agreement.** In the event of any ambiguity in this Agreement or other issue arising out of this Agreement, the resolution of such ambiguity or issue shall not be resolved against the Party that drafted this Agreement merely because such Party drafted that portion of the Agreement.

(g) **Compliance with Laws.** Each Party will comply with all applicable federal, state, and local laws and regulations applicable to the Proposal, or any foreign equivalent thereof, including without limitation, all applicable Healthcare Laws. "**Healthcare Laws**" means (a) Titles XVIII and XIX of the Social Security Act, the Federal False Claims Act, the Federal Anti-Kickback Law, the Health Information Portability and Accountability Act ("**HIPAA**"), the Health Information Technology for Economic and Clinical Health Act ("**HITECH**"), the Stark Law, 21 C.F.R. Part 11, any and all analogous or similar federal, state and international laws, and any and all amendments to the foregoing; (b) any and all other current or future federal, state and international healthcare laws applicable to the Services and any and all amendments to the foregoing; and (c) any and all statutory citations, regulations, policies, procedures,

guidance, instructions and requirements, whether issued by the Centers for Medicare and Medicaid Services or other federal, state or international administrative or governmental bodies, under or related to the foregoing (a) or (b).

(h) **Authority.** Each Party represents and certifies that it has the full right and authority to enter into this Agreement and that it has no obligations, commitments or restrictions preventing such.

(i) **Audit Rights.** During the term of this Agreement and for a period of three (3) years thereafter, CDAF shall have the right, upon sixty (60) days written notice, to send its auditors to Recipient's business offices to conduct a semi-annual review or audit of Recipient's books, records and accounts as they pertain to CDAF's Award funds.

IN WITNESS WHEREOF, intending to be legally bound, Recipient and CDAF have executed or caused this Agreement to be executed by their duly authorized representatives as of the Effective Date.

CENTER FOR DISEASE ANALYSIS FOUNDATION, INC.	**RECIPIENT** **recipient**
BY: _____	BY: _____
Printed Name: _____	Printed Name: _____
Title: _____	Title: _____

CAMEO Request for Proposal (RFP)

Community Actions in Materials, Education, and Outreach for Women & HIV

Strengthening women's HIV prevention and treatment literacy through community-led action

Overview

Women and adolescent girls in all their diversity—including cisgender and transgender women—remain a critical yet often underserved population in the global HIV response, facing persistent inequities across prevention, diagnosis, and care. Globally, women and girls accounted for approximately 45% of new HIV infections in 2023 (UNAIDS, 2024). Young women aged 15–24 remain particularly vulnerable, representing about 63% of new HIV infections among young people worldwide (UNAIDS, 2024). Transgender women also experience a disproportionately high burden of HIV and are estimated to be more than 10 times more likely to be living with HIV than the general adult population (UNAIDS, 2023; Baral et al., 2013). These inequities are further intensified for women navigating overlapping vulnerabilities such as housing instability, rural isolation, criminal legal system involvement, migration, poverty, and substance use.

Community-based and advocacy organizations play a critical role in ensuring women have access to trusted, culturally relevant information and the tools needed to make informed decisions about HIV prevention, treatment, and overall well-being. While substantial information and resources already exist, significant gaps remain in ensuring that this information reaches—and resonates with—the women who need it most.

The CAMEO (Community Actions in Materials, Education, and Outreach for Women & HIV) Request for Proposal (RFP) seeks to support initiatives that strengthen HIV prevention and treatment literacy through education, materials development, outreach, and community-led engagement. Applicants should clearly describe how proposed materials and resources will be disseminated to reach women in meaningful ways, ensuring that information is accessible, relevant, and responsive to their lived experiences.

Proposals may focus on women from diverse backgrounds, including adolescent girls and young women, transgender women, migrant women, women involved in the criminal legal system, women experiencing housing instability, women living in rural or underserved communities.

The CAMEO RFP will encompass only the following eligible **countries:** Australia, Canada, China, France, Germany, Italy, Japan, Spain, the United Kingdom, and the United States**. Organizations that are legally registered and operating within these countries are eligible to apply. In addition,** pan-regional or global organizations that are not registered in these countries but have demonstrated programs, partnerships, or activities serving communities within one or more of the eligible countries may also be considered**,** provided the proposal initiative clearly focuses on populations within the listed countries.

Program Focus Areas

Gilead will evaluate and potentially support proposals that address one or more of the following:

1. Women-Centered HIV Awareness, Prevention, and Treatment Literacy

Projects in this area should focus on strengthening women's awareness, knowledge, and confidence to make informed decisions about HIV prevention, testing, and treatment. While significant progress has been made in HIV education, many women remain unaware of their potential risk or may not perceive HIV as relevant to their communities. Addressing these foundational gaps in understanding is essential to supporting informed decision-making and engagement with HIV prevention and treatment services.

Proposed activities may include:

Foundational Awareness and HIV Literacy

Projects may include activities such as:

- **Developing foundational HIV education and awareness materials** that help women understand what HIV is, how it is transmitted, and why HIV testing, prevention, and treatment are relevant to their health and communities.
- **Providing status-neutral education about HIV testing and the HIV continuum**, helping women understand what HIV testing is, what different results may mean, and the range of prevention and treatment approaches that may be considered following a test result.

Prevention and Treatment Literacy

Projects may include activities such as:

- **Creating educational materials and outreach initiatives that increase awareness of HIV prevention strategies**, such as barrier protection, pre-exposure prevention approaches, and post-exposure prevention options, using language and formats that resonate with women.

- **Supporting women's understanding of HIV treatment and long-term health, across the life course**, including treatment literacy, the importance of consistent medication use as prescribed by healthcare providers, achieving viral suppression, and the meaning of U=U (Undetectable = Untransmittable).

Dissemination and Community Engagement

Projects may include activities such as:

- **Using multichannel communication and community engagement strategies** (e.g., digital content, peer outreach, workshops, social media, print materials) to ensure that information reaches diverse groups of women in culturally relevant and accessible ways.
- **Developing dissemination approaches that ensure materials reach women who may face barriers to accessing traditional health information**, including community-based outreach, peer networks, and partnerships with trusted local organizations.

Applicants are encouraged to clearly describe **how educational materials or resources will be distributed and reach the intended audience**, including through community partnerships, peer networks, digital platforms, or other outreach approaches.

2. Improving Quality of Life for Women Across the HIV Continuum

Projects in this area may focus on strengthening women's emotional, physical, reproductive, and psychosocial well-being through educational, informational, and peer-centered approaches. Supporting these areas can help improve self-efficacy, address stigma related to HIV and sexual health, and strengthen women's confidence in making informed decisions about prevention, care, and long-term health. Initiatives may address the needs of women both living with HIV and those who may benefit from HIV prevention education, with the goal of promoting overall well-being and sustained engagement with health services across the HIV continuum.

Activities may include:

- Developing educational resources that support women across life stages—including adolescent girls and young women, pregnancy and postpartum periods, peri/menopause, and aging—while addressing topics relevant to women both living with HIV and those seeking to maintain their HIV-negative status. Materials should be informational and educational in nature and should not provide medical or therapeutic services or advice.
- Providing educational tools and resources that support trauma-informed approaches to well-being, including strategies that help women better understand mental and emotional health, reproductive health decision-making, and navigating health systems.
- Strengthening peer support networks that promote empowerment, shared learning, and community connection, helping women build confidence in engaging with HIV prevention education when appropriate and supporting long-term well-being for women living with HIV.

3. Addressing Stigma, Strengthening Engagement in Care and Advancing Inclusion

Projects in this area may focus on reducing barriers and creating supportive, affirming environments for women across the HIV prevention and treatment continuum. Activities may include:

- Developing initiatives that challenge HIV stigma, gender-based discrimination, and harmful gender norms through education, storytelling, and community engagement.
- Elevate the lived experiences and voices of women to foster empathy, shift narratives, and normalize dialogue about HIV prevention and treatment.
- Supporting educational and community-led efforts that foster stigma-free, supportive environments where women can access information, explore sexual health and broader HIV-related topics, and feel empowered to engage with health services
- Centering women who face intersecting vulnerabilities—such as incarceration or reentry, migration, housing instability, rural residence, substance use, or experiences of gender-based violence.

Collaborative proposals involving partnerships between community organizations, advocacy groups, or women-led networks are encouraged where such partnerships strengthen the reach or impact of the proposed initiative.

Expectations for Selected Organizations

Organizations that receive CAMEO funding are expected to:

- **Actively involve women—cisgender or transgender—with lived experience, as well as relevant community partners**, in the design and/or delivery of project activities where appropriate.
- **Implement educational, outreach, or materials-focused initiatives** aligned with one or more of the CAMEO program areas.
- **Track and report measurable, non-clinical outcomes**—such as engagement, reach, knowledge gains, resource utilization, or participant feedback—to help assess the impact of the proposed activities.
- **Participate in periodic project check-ins**, including quarterly meetings with the program's implementation partner/vendor, to share updates on project progress, lessons learned, and any implementation considerations.
- **Submit required final reporting**, including a summary of activities, key learnings, and financial reconciliation in accordance with Gilead's reporting requirements.

- **Where feasible, consider approaches for sharing or disseminating project insights, learnings, or resources** with relevant communities or stakeholders to help extend the impact of the initiative.

Application Requirements

Organizations must submit a complete **Letter of Intent (LOI)** through the CAMEO RFP submission portal. LOIs should be concise and include the following components:

- **Organization background and relevant experience**, including prior work in women's health, HIV prevention or treatment literacy, stigma reduction, advocacy, or community outreach.

- **Project description**, including goals, planned activities, target population(s) of women (cisgender, transgender), geographic focus, and anticipated timelines.

- **Total estimated project budget**, not to exceed **$50,000 USD** (or equivalent in local currency), including all direct project-related costs.

- **Measurement and evaluation plan** outlining non-clinical indicators such as engagement, reach, knowledge gains, resource utilization, participant feedback, or other educational outcomes.

- **Overview of intended partnerships or collaborations**, including involvement of women with lived experience or community organizations where appropriate.

- All applications and associated activities **must not make any mention to specific medicines, treatments or medical devices.**

High-scoring LOIs are invited to submit a full proposal with a detailed budget and implementation plan via SteepRock (gilead.steeprockinc.com).

Eligibility Criteria

Country Participation

The CAMEO RFP is open only to organizations operating in the following eligible countries:

- Australia
- Canada
- China
- France
- Germany

- Italy
- Japan
- Spain
- United Kingdom
- United States

Applicants must be legally able to receive funding and implement programs within one or more of these countries.

Eligible Organizations

Eligible applicants include registered **non-profit or charitable organizations**, such as:

- Community-based organizations (CBOs)
- Advocacy organizations
- Women's health and wellness organizations
- HIV service organizations
- Grassroots or community networks

In countries where non-profit registration is not possible, **for-profit entities** may apply **only if** they operate exclusively for educational, advocacy, outreach, or other community-support purposes and not for commercial healthcare delivery. In any case, eligible applicants must have legal capacity to enter into the relevant funding agreement.

Experience and Mission Alignment

Organizations **do not need to have prior experience delivering HIV-specific programming** to be eligible for CAMEO RFP funding.

Experience with target communities: Preference may be given to organizations with a proven track record of working with the patient populations or communities relevant to the proposed project.

CAMEO welcomes applications from:

- Organizations with experience in HIV prevention, treatment education, efforts to address HIV stigma, or related community initiatives supporting women's health and well-being
- Women-centered organizations that have not previously worked in the HIV field but have strong relationships with women and seek to integrate HIV awareness education, or dialogue into their existing work.

Organizational Capacity and Compliance

Applicants must demonstrate:

- Capacity to implement and manage a project of comparable scope
- Appropriate staffing, governance, and financial oversight
- Compliance with all applicable local laws and regulations, including but not limited to, data protection, anti-bribery, and anti-corruption laws.
- Transparency in financial practices and willingness to meet reporting requirements, including but not limited to, segregated accounting for grants and documented expenditure tracking, providing supporting documentation on request
- Ensure inclusivity and cultural sensitivity in program design and delivery
- Independence from commercial healthcare entities (or disclosure of relevant relationships)
- Submit medicines agnostic proposals
- Organizations will produce the materials and activities independently. Gilead will not exercise any influence regarding the creation of these materials and activities; therefore, the organizations will remain legally responsible for the accuracy of the content created and for its compliant distribution.

For best transparency practices, Gilead's funding should be acknowledged in any material or activity created under the scope of this project. The following disclosure should be added to the relevant materials: "This material/activity was funded with a Gilead grant". Experience working with women affected by or vulnerable to HIV is welcomed but not required. Equal consideration will be given to women-centered organizations that demonstrate strong community trust and a clear plan to integrate HIV education into their existing work.

Review Process

LOIs will be reviewed through a blinded process by an internal Gilead review committee, with identifying organizational information removed. Reviewers will evaluate how well the proposed initiative aligns with the objectives of the CAMEO RFP, the strength and clarity of the proposed approach, the organization's experience and credibility within the communities it serves, the feasibility of the proposed activities, and the potential for meaningful impact.

This is a competitive process in which submissions will be evaluated based on their overall strengths. Organizations with the highest-scoring LOIs will be invited to submit a full proposal, including a detailed budget appropriate to the scope of the proposed activities. Full proposals will undergo a similar review process.

LOIs will be assessed based on the following criteria:

- Alignment with CAMEO objectives, including a clear focus on women-centered education, materials development or adaptation, outreach, and efforts to address HIV stigma across prevention and treatment.

- Strength and clarity of the proposed approach, including how HIV education will be delivered and effectively reach the intended population of women in ways that are appropriate for the communities served.
- Credibility, trust, and reach within the communities of women served, including demonstrated relationships with women who may benefit from the proposed activities.
- Readiness and feasibility, including the organization's capacity to implement the proposed activities within the proposed timeline and budget.
- Integration of HIV education into existing initiatives, including thoughtful approaches from organizations that are new to HIV-related work but seek to incorporate HIV education, awareness, or dialogue into their current activities.
- Appropriateness of proposed outcomes and evaluation methods, with emphasis on non-clinical, educational, and engagement-related measures such as reach, participation, knowledge gains, resource utilization, or participant feedback.

Potential for impact and learning, including approaches that may inform future community-based efforts to engage women around HIV, as well as—where appropriate—the potential for proposed activities or resources to be sustained, expanded, or adapted beyond the initial funding period

Prior experience delivering HIV-focused initiatives is not required and will not be weighted more heavily than demonstrated community trust, relevance, and readiness to integrate HIV education into existing activities

LOIs identified as the strongest submissions will be discussed by a multidisciplinary review committee. Selected applicants will be invited to submit a full proposal, including a detailed budget and implementation plan. Final funding decisions will be made following review of the full proposals.

Funding Parameters & Budget Considerations

Gilead intends to award up to **$500,000 USD** in total funding through the CAMEO RFP, subject to the availability of funds and the receipt of meritorious applications.

Individual project requests **must not exceed $50,000 USD** (or the equivalent in local currency). Applicants are encouraged to request funding amounts that are appropriate to the scope, scale, and objectives of their proposed project. **There is no expectation that applicants request the maximum award amount.**

Projects should be designed for completion within a **12–18 month** implementation period.

Budgets should reflect **reasonable and necessary costs** directly related to the development and delivery of approved educational materials, outreach activities, and community-based programming. Proposed budgets should be clearly itemized and aligned with the planned activities described in the application.

For applicants based outside the United States, budgets may be submitted in **local currency**, with a clear indication of the total requested amount and an approximate USD equivalent for reference.

Organizations should disclose any sources of funding that may be supporting their proposals. Funding overlap should be avoided. Otherwise, Gilead reserves the right to request recovery of any misused funds.

Funding decisions will be made following review of LOIs and invited full proposals. Organizations with the strongest LOI submissions will be invited to submit a full proposal through the SteepRock grants management system (gilead.steeprockinc.com), including a detailed budget and implementation plan. Additional submission instructions will be provided to invited applicants. Final funding decisions will be made after review of the full proposals.

Allowable & Restricted Costs

Allowable Costs

CAMEO funding may be used to support non-clinical, educational, and community-based activities, including but not limited to:

- Development, adaptation, translation, and dissemination of awareness and educational materials (e.g., print materials, toolkits, videos, digital content, social media assets).
- Community education and outreach activities, including workshops, forums, listening sessions, peer-led discussions, and informational events.
- Peer education and peer support activities focused on knowledge-sharing, empowerment, addressing HIV stigma, and navigation of HIV prevention and treatment information.
- Advocacy and awareness-building activities aimed at addressing HIV stigma, shifting narratives, and elevating women's voices, provided such activities do not involve government lobbying.
- Culturally and linguistically appropriate adaptations of materials to reach diverse groups of women.
- Reasonable personnel, consultant, and operational costs directly related to the development and delivery of the approved materials, activities or initiatives.
- Evaluation-related costs associated with measuring non-clinical outcomes such as reach, engagement, knowledge gains, and dissemination of project learnings.

Restricted Costs

CAMEO funding may not be used to support:

Individuals (including, without limitation individual health care providers, patient organization representatives and/or government officials) or physician group practices

Organizations that:

- Are not legally registered as charitable/non-profit, except in countries where non-profit registration is not available or feasible. In such cases, eligible entities must operate solely for educational, advocacy, outreach, or other community-focused purposes and must not engage in commercial healthcare delivery or profit-generating clinical services.
- Were established or registered as charitable after 1 December 2023
- Primarily promote political or religious viewpoints to the people they support
- Are unable to supply appropriate documents including those listed above.

The fund **cannot** be used for:

- Expenditure which will have already taken place when the grant is offered.
- Any grants, bursaries, sponsorship or financial donations to other organizations or individuals.
- Capital equipment or significant items to purchase i.e. laptops or mobile phones.
- Medications or purchasing of medications.
- Direct medical expenses, including labs.
- Existing deficits.
- Basic biomedical research, Gilead-sponsored clinical research or clinical trials.
- Projects that directly influence or advance Gilead's business, including purchase, utilization, prescribing, formulary position, pricing, reimbursement, referral, recommendation or payment for products.
- Events or programs that already occurred.
- Government lobbying activities.
- Organizations that discriminate on the basis of race, color, gender, religion, disability, sexual orientation, or gender identity or expression.

Reporting Requirements

Organizations receiving CAMEO funding will be required to complete standard reporting activities to document activity implementation and outcomes in SteepRock (gilead.steeprockinc.com).

At a minimum, awardees will be expected to submit:

- Quarterly updates through the CAMEO RFP reporting process and participate in quarterly virtual meetings to share progress and key updates.
- A final narrative report summarizing project activities, target audiences reached, materials or resources developed, key outcomes, challenges encountered, and lessons learned submitted into SteepRock.

- A final financial reconciliation, comparing actual expenditures to the approved budget and explaining any material variances.
- Any required transparency or transfer-of-value (ToV) reporting, in accordance with applicable local laws, regulations, and Gilead policies.

Reporting should focus on non-clinical outcomes, such as reach, engagement, participation, knowledge gains, or feedback related to educational and outreach activities. Awardees are not expected to collect or report individual-level health data or clinical outcomes.

Gilead may request reasonable clarifications or follow-up information to support reporting and program evaluation.

No Guarantee of Funding

Submission of an LOI or full proposal does not guarantee funding. Gilead may approve or decline applications at its sole discretion.

No Inducement or Reward

Awards are not provided as an inducement or reward for purchasing, recommending, or prescribing Gilead products.

Submission Timeline

- RFP Issue Date: 8 June 2026
- LOI portal submission window: 15 June 2026 – 15 July 2026
- Anticipated LOI notification: 29 July 2026
- Full proposal submission: 28 August 2026 by 11:59 PST
- Award Announcement: 11 September 2026

EXHIBIT B
Recipient Proposal

EXHIBIT C
Recipient Budget Details

Exhibit D
Recipient Timelines